ID | 1071 |
Name of the vaccine | Daptacel |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 6 weeks to 6 years |
Description of the vaccine | Diphtheria, Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 2002 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | After the third dose, 100% achieved tetanus antitoxin levels of greater than or equal to 0.10 IU/mL. While 98.8% achieved levels of greater than or equal to 1.0 IU/mL after the fourth dose. |
Vaccine formulation | Suspension for injection |
Dosage | The five dose immunization series administered at 2, 4, 6 and 15-20 months of age, and at 4-6 years. |
Mechanism of action | Serum tetanus antitoxin level of greater than or equal to 0.1 IU/mL is protective. |
Route of administration | Intramuscular |
Indications | Used to complete the immunization series in infants who have received 1 or more doses of whole-cell pertussis DTP. |
Export | Distributed by- Sanofi Pasteur Inc., USA |
Approval | US FDA |
Adjuvant | Aluminium phosphate |
Repurposing | Could be used for diphtheria and pertussis. |
Side effects of vaccine | Fussiness, inconsolable crying, and decreased activity/lethargy, fever, tenderness, redness and increase in arm circumference. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT00258895 |
Reference | https://www.fda.gov/media/74035/download |
Other name | NA |
Additional Links | NA
|